Traws Pharma (TRAW) Competitors

$0.65
+0.00 (+0.68%)
(As of 03:20 PM ET)

TRAW vs. NERV, COCP, TNXP, VAXX, NNVC, AYTU, TLPH, VBIV, INDP, and NRSN

Should you be buying Traws Pharma stock or one of its competitors? The main competitors of Traws Pharma include Minerva Neurosciences (NERV), Cocrystal Pharma (COCP), Tonix Pharmaceuticals (TNXP), Vaxxinity (VAXX), NanoViricides (NNVC), Aytu BioPharma (AYTU), Talphera (TLPH), VBI Vaccines (VBIV), Indaptus Therapeutics (INDP), and NeuroSense Therapeutics (NRSN). These companies are all part of the "pharmaceutical preparations" industry.

Traws Pharma vs.

Minerva Neurosciences (NASDAQ:NERV) and Traws Pharma (NASDAQ:TRAW) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, community ranking, valuation, risk, dividends, media sentiment and earnings.

Minerva Neurosciences has a net margin of 0.00% compared to Minerva Neurosciences' net margin of -8,384.07%. Traws Pharma's return on equity of 0.00% beat Minerva Neurosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Minerva NeurosciencesN/A N/A -53.19%
Traws Pharma -8,384.07%-113.18%-65.76%

Minerva Neurosciences received 347 more outperform votes than Traws Pharma when rated by MarketBeat users.

CompanyUnderperformOutperform
Minerva NeurosciencesOutperform Votes
347
60.66%
Underperform Votes
225
39.34%
Traws PharmaN/AN/A

Minerva Neurosciences currently has a consensus target price of $7.00, indicating a potential upside of 180.00%. Given Traws Pharma's higher probable upside, analysts plainly believe Minerva Neurosciences is more favorable than Traws Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Minerva Neurosciences
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Traws Pharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

34.6% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 7.9% of Traws Pharma shares are held by institutional investors. 6.4% of Minerva Neurosciences shares are held by insiders. Comparatively, 3.3% of Traws Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Minerva Neurosciences has a beta of 0.27, meaning that its share price is 73% less volatile than the S&P 500. Comparatively, Traws Pharma has a beta of 1.43, meaning that its share price is 43% more volatile than the S&P 500.

Traws Pharma has higher revenue and earnings than Minerva Neurosciences. Traws Pharma is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Minerva NeurosciencesN/AN/A-$30M-$4.47-0.56
Traws Pharma$226K72.77-$18.95M-$0.91-0.71

In the previous week, Minerva Neurosciences had 3 more articles in the media than Traws Pharma. MarketBeat recorded 4 mentions for Minerva Neurosciences and 1 mentions for Traws Pharma. Minerva Neurosciences' average media sentiment score of 1.89 beat Traws Pharma's score of 0.06 indicating that Traws Pharma is being referred to more favorably in the news media.

Company Overall Sentiment
Minerva Neurosciences Neutral
Traws Pharma Very Positive

Summary

Minerva Neurosciences beats Traws Pharma on 9 of the 14 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRAW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TRAW vs. The Competition

MetricTraws PharmaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$16.45M$6.63B$4.99B$7.85B
Dividend YieldN/A2.76%39.14%3.93%
P/E Ratio-0.7112.70139.0215.52
Price / Sales72.77262.152,426.2877.36
Price / CashN/A20.5632.7828.46
Price / Book1.275.945.014.47
Net Income-$18.95M$137.03M$103.74M$216.32M
7 Day Performance-2.05%-1.27%-0.05%1.29%
1 Month Performance-8.90%-2.78%-0.37%1.60%
1 Year PerformanceN/A-0.83%5.72%10.85%

Traws Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NERV
Minerva Neurosciences
3.7129 of 5 stars
$2.39
-4.8%
$7.00
+192.9%
-65.9%$16.36MN/A-0.539Short Interest ↓
COCP
Cocrystal Pharma
2.851 of 5 stars
$1.73
-1.1%
$10.00
+478.3%
-34.0%$16.38MN/A-0.8712Analyst Forecast
News Coverage
High Trading Volume
TNXP
Tonix Pharmaceuticals
2.8974 of 5 stars
$0.17
-5.5%
$5.50
+3,103.3%
-91.1%$16.39M$7.77M-0.02103Analyst Forecast
News Coverage
VAXX
Vaxxinity
3.7474 of 5 stars
$0.05
-54.1%
$7.00
+13,625.5%
-97.6%$16.48M$70,000.00-0.1157Short Interest ↓
NNVC
NanoViricides
0 of 5 stars
$1.87
+2.2%
N/A+56.9%$16.49MN/A-2.317News Coverage
Gap Up
High Trading Volume
AYTU
Aytu BioPharma
3.2831 of 5 stars
$3.24
+0.9%
$5.00
+54.3%
+79.9%$17.04M$107.40M-0.80150Gap Up
TLPH
Talphera
1.5534 of 5 stars
$1.01
-1.0%
$4.50
+345.5%
N/A$17.16M$651,000.00-0.6815Short Interest ↑
News Coverage
Gap Down
VBIV
VBI Vaccines
1.7403 of 5 stars
$0.62
+3.3%
N/A-78.8%$17.21M$8.68M-0.05131Upcoming Earnings
Analyst Forecast
Short Interest ↓
News Coverage
INDP
Indaptus Therapeutics
3.1682 of 5 stars
$2.15
+2.9%
$12.00
+458.1%
+0.5%$17.33MN/A-1.177Positive News
Gap Up
NRSN
NeuroSense Therapeutics
0 of 5 stars
$1.18
+0.9%
N/A-32.7%$17.36MN/A-1.4218Gap Down

Related Companies and Tools

This page (NASDAQ:TRAW) was last updated on 5/14/2024 by MarketBeat.com Staff

From Our Partners